331828-49-0 Usage
Uses
Used in Pharmaceutical Drug Synthesis:
1-(4-nitro-benzenesulfonyl)-piperidine-4-carboxylic acid is used as a key intermediate in the synthesis of pharmaceutical drugs. Its structural diversity and the presence of the nitrobenzenesulfonyl group enable the creation of a wide range of analogs and derivatives with potential therapeutic applications.
Used in Bioactive Compound Synthesis:
In the field of medicinal chemistry, 1-(4-nitro-benzenesulfonyl)-piperidine-4-carboxylic acid is utilized as a starting material for the synthesis of bioactive compounds. Its unique structural features and the ability to modify the molecule through the nitrobenzenesulfonyl group make it an attractive candidate for the development of new drugs with specific biological activities.
Used in Medicinal Chemistry Research:
1-(4-nitro-benzenesulfonyl)-piperidine-4-carboxylic acid serves as a valuable tool in medicinal chemistry research. Its potential to be modified and functionalized allows researchers to explore various avenues in drug development, including the creation of novel compounds with targeted applications and the enhancement of existing drug therapies.
Overall, 1-(4-nitro-benzenesulfonyl)-piperidine-4-carboxylic acid is a promising compound in the field of medicinal chemistry, with applications in drug synthesis, bioactive compound development, and research. Its versatility and potential for modification make it a valuable asset for the advancement of pharmaceutical drug development and the discovery of new therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 331828-49-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,1,8,2 and 8 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 331828-49:
(8*3)+(7*3)+(6*1)+(5*8)+(4*2)+(3*8)+(2*4)+(1*9)=140
140 % 10 = 0
So 331828-49-0 is a valid CAS Registry Number.
331828-49-0Relevant academic research and scientific papers
TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
-
Page/Page column 131-132, (2011/06/16)
Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.
